: - - : ( ) - -

1. 1

:

2. 45

3. 69

4. 85

5. 99

-

6. 127

7. 141

8. 157

9. 183

10. 201

11. 227

12. 247

13. 263

14. 301

( )

15. 329

( )

16. 377

17. 391

18. 405

:

19. 425

20. 443

21. 457

. . . . . . . . . . . 2 . . 4 6 . 7 10 . 11 12 . 13-21 .

. . . 1 13 . . . : UCBInc U.S.A. (GPTAD) UCB UCBInc U.S.A. . . . (nm) 9-10 . " " 1974 . 100 2/0 . 1 (1).

1. ( .) . 100 2/0 . : 1. 25 . ( ) . . . . . 30 5% 10 20% 3 50% (1). . . . .

. ( ) . . ( ) . : (TEM) (SEM) [ (SPM)] ( ). TEM . . TEM . TEM .

SEM TEM 1 . 1 . ( ) SPM . . . 1986 . SPM . ( )

( ) . . . DNA . . 1 .

. . 2 (1). 1.

(2)

X

(3)

EM (4)

DLS TEM (5)

DLS TEM (6)

ELISA (7)

(8)

TEM(9)

: DLS ELISA EM NP TEM .

: . . 3 (1).1. . . (1).

2. .

: MEMS . : 1.

3. : 1.

2. . SPM . . . . . ( ) . ( 1) . . (10). (NPDDSs) . (11). (SLNs) . (12) - (13) - . (14) - . (15) (18-16 5-2) . (19) NPDDS . (26-20) NPDDS (17). NPDDS . . " " . . . NPDDS (31-27). . . . NPDDS . . . . . NPDDS . - . (3233). - 1990 (). . () (36). (11). . ( ) (14). : (14). : . : - 15HS solutol ( 4) F solutol/Foil 100S Lipoid/15HS solutol (37). (38) (15). - (39). (44-403814)

4. . : 37. (3245). - ( ) . . ( ) . . (37). (2) - . . . Cryo-TEM . - DNA (46). DNA - (47). (47) (TAT) TAT 1-HIV - (PEI) . . (48) - (DNA) . . DNA DNA (38). (49) - DNA . (50) . 8R . . ( 5: ). (51) . - (52). (53) - . - 106 . 87% . (54) . (55) . (56) 38SN . (HSA) . . 38SN .

5. . : 50. (). (CMC) . CMC . CMC CMC (58). . CMC . CMC CMC . CMC . (59). (59). - (60). ( ) (61). . - . . . (62). . (63). - . (64). (65). . . () . (66). . . . . . (67). . . 10 100 . (68). (69) (44). (44). 6 - .

6. - . : 44.

. . 9EPR . (70). EPR (71) . . (72) A . (HPC) A . HPC 2Caco- . . (73) (74) - -(75) (76) . (77). (78). (79). (77). (80). . . . . . (81). . . . . (8283). . . / pH . (81).

(8584). . . . . (86). . (87). ( ) (88). (89) (--)--(--) (PCLLAPEGPCLLA) . . . . (90). (93-91). (94) PLGA-PEG . . (60). ( )( ) (95) . (98-96) . 2 . (2--2-)-- (99) (100) PLGA (101) (102) (103) . 2.

(n- )

( )(N-) LCST

()PEOPPOPEO Pluronics

[ -b-( )

PEOPPOPAA graft copolymer

PL(G)A/PEO/Pl(GA) copolymersPLGAPEOPLGA (LCST)

PVA-g-PLGA graft polymers

PEGTPBT copolymers (polyactive)

MAoligolactidePEOoligolactideMA

: 104.

(66). . (105) (106) . . . . (107) . (108) . 128-105 . 3CaCO .:

5000 . DNA . (112-109). DNA . DNA . . "" / (95). (109) HSA . . . . (ODN)/ . : (PTOs) ODNs () (109). D- N--D- b-(14) (116-113). . . . . (117) . (103) - . . (119) . . (FITC) . (120). (121). DNA . (122) . 50 70 . (123) . . . . (126-124). . (127) . . . 1970 . (128). 100 . . . . (128) 200 . 200 . (atRA) . atRA . atRA . . -atRA atRA . atRA (129-131). -T (132). . . ( ) (133). (134) (135136) (137) . . (138). . 400PEG 80 F 213 TPI (138). -- (PDLLA) -- (PLGA) PDLLA PLGA 10 (139). ( -- )(PVA/MA) - . (140) . DNA PLGA (--) PLA-PEG ( (-)-(()) (141). DNA 20 DNA . DNA . (142) (143) DNA (144) . NN- . 30 50 . (66). (130). (146147). (148). . . (149) . (N-) . (150). 1-HIV 1-HIV . ( ) ( 400 ) 1-HIV 60 . 1-HIV (150). (151). (152) . . . (152). (153) . .

( ) () . (51/1 ) 300 . (CV 2-1%) 68/1 . (154).

10% (154). (PLA) . ( ) . PLA 02/1 . 1% (10 ) pH . pH .

250 90 % . 50 100 130 250 . " " . . 250-2 ( CV 5 15%). . 4HAuCl . . 14 . 4 . (154). . 250-2 ( CV 10 20%).

2 . ( 04/1) 500 . . . DNA . -2NH -COOH A NHS NTA EDTA (154). (155) . 100 10 . (155). ( ) . . . . A NHS NTA EDTA . DNA . 15 . (156). 1991 (157). (158). . (159).

.

. . (DNA RNA) . (160). DNA RNA (161162). . . . . . . . . (163).

. (163). . . . . (164).

. (163). . . (165166). (CNSs) . CNS . . (163).

. . . . () () KLH (169167-154). nano-HPLCMS/MS . (ROMP) . ROMP . nano-HPLCMS/MS . IgG 7/0 9/0 . . 14 2/0 1045/1 IgG 4 FITC-IgG . (170). (171). F127 . (172). . . . 10 pH 8/4 2/7 . . . (172).

. . (Glioma L9) (Choriocarcinoma 3JEG) . 90% (173). . DNA . . DNA . DNA . . . (173).

. . (-(2-)-b-( )-b-(2- ) . 1A . . . (174). . / 5 30 / ( ) (175). : () () (176). . . ( ) . (177). 500 . (178).

. . . (164).

1.The Royal Society. Nanoscience and nanotechnologies: opportunities and uncertainties. London: Royal Society, 2004:4.

2.Jores K, Mehnert W, Mader K. Physicochemical investigations on solidlipid nanoparti-cles and on oil loaded solidlipid nanoparticles: a nuclear magnetic resonance and elec-tron spin resonance study. Pharm Res 2003; 20:1274.

3.Maestrell F, Mura P, Alonso MJ. Formulation and characterization of triclosan sub-micron emulsions and nanocapsules. J Microencapsul 2004; 21:857.

4.Lochmann D, Vogel V, Weyermann J, et al. Physicochemical characterization of protamine-phosphorothioate nanoparticles. J Microencapsul 2004; 21:625.

5.Geze A, Putaux JL, Choisnard L, Jehan P, Wouessidjewe D. Long term shelf stability of amphiphilic B-cyclodextrin nanospheres suspensions monitored by dynamic light scat-tering and cryo-transmission electron microscopy. J Microencapsul 2004; 21:607.

6.Wang X, Dai J, Chen Z, et al. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH sensitive nanoparticles for oral administration. J Control Release 2004; 97:421.

7.Yoo HS, Park TG. Biodegradable nanoparticles containing proteinfatty acid complexes for oral delivery of salmon calcitonin. J Pharm Sci 2004; 93:488.

8.Mo Y, Lim LY. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nano particles by A549 cells. J Pharm Sci 2004; 93:20.

9.Alphandary HP, Aboubaker M, Jaillard D, Couvreur P, Vauthier C. Visualization of insu-lin loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm Res 2003; 20:1071.

10.Hoet P, Hohlfeld IB, Salata OV. Nanoparticlesknown and unknown health risks. J Nanobiotechnol 2004; 2:12.

11.Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solidlipid nanoparticles. J Control Release 2004; 95:627.

12.Dingler A, Gohla S. Production of solidlipid nanoparticles (SLN): scaling up feasibilities. J Microencapsul 2002; 19:11.

13.Gasco MR. Method for producing solidlipid microspheres having narrow size distribu-tion. US Patent 5,250,236, 1993.

14.Mehnert W, Mader K. Solidlipid nanocapsules production, characterization and appli-cations. Adv Drug Deliv Rev 2001; 47:165.

15.Muller RH, Mader K, Gohla S. Solidlipid nanoparticles (SLN) for controlled drug deliverya review of the state of the art. Eur J Pharm Biopharm 2000; 50:161.

16.Beck RCR, Pohlman AR, Guterres SS. Nanoparticles-coated microparticles: preparation and characterization. J Microencapsul 2004; 21:499.

17.Rodriguez SG, Allemann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticles formation in the salting out, emulsification-diffusion and nanopre-cipitation methods. Pharm Res 2004; 21:1428.

18.Liao X, Wiedmann TS. Measurement of process-dependent material properties of pharmaceutical solids by nanoindentation. J Pharm Sci 2004; 94:79.19.Rigaldie Y, Largeteau A, Lemagnen G, et al. Effects of high hydrostatic pressure on several sensitive therapeutic molecules and a soft nano-dispersed drug delivery system. Pharm Res 2003; 20:2036.

20.Fruhling J, Penasse W, Brassine C, et al. Intracellular penetration of liposomes containing a water insoluble antimitotic drug in L1210 cells. Eur J Cancer 1980; 16:1409.

21.Laurent G, Laduron C, Ruysschaert JM, Deleers M. Inhibition of cationic liposomes of 3H-thymidine incorporation into DNA of L1210 cells. Res Commun Chem Pathol Pharmacol 1981; 31:515.

22.Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of Nifedipine. Int J Pharm 2005; 299:167177.

23.Hecq J, Deleers M, Fanara D, et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of UCB-35440-3, a highly-dosed poorly water soluble weak base. Eur J Pharm Biopharm 2006; 64:360368.

24.Vranckx H, Demoustier M, Deleers M. Pharmaceutical composition comprising nano-capsules. US Patent 05500224, March 19, 1996.

25.Fanara D, Grognet P, Berwaer M, Deleers M. Use of pharmaceutical compositions capa-ble of being gelled in Periodontology. US Patent 6471970, WO 09956726, EP 01073414, October 29, 2002.

26.Fanara D, Berwaer M, Deleers M. Pharmaceutical compositions capable of being gelled. US Patent 6464987, WO09956725, EP01073415, October 15, 2002.

27.LaVan DA, McGuire T, Langer R. Small scale systems for in vivo drug delivery. Nat Biotechnol 2003; 21:1184.

28.Saltzman WM, Olbricht WL. Building drug delivery into tissue engineering. Nat Rev 2002; 11:177.

29.Ziaie B, Baldi A, Lei M, Gu Y, Siegel RA. Hard and soft micromachining for biomems: review of techniques and examples of applications in microfluidics and drug delivery. Adv Drug Deliv Rev 2004; 56:145.

30.Su YC, Lin L. A water powered microdrug delivery system. J Electrochem Syst 2004; 13:75.

31.McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles for gene and drug delivery. Annu Rev Biomed Eng 2000; 2:289.

32.eurtault B, Saulnier P, Benoit JP, Proust JE, Pech B, Richard J. Lipid nanocapsules, preparation, method and use as a medicine. Patent No. W001/64328, 2000.

33.Heurtault B, Saulnier P, Pech B, Benoit JP, Proust JE. Interfacial stability of lipid nanocap-sules. Colloids Surf B Biointerfaces 2003; 30:225.

34.Muller RH, Dingler T, Schneppe T, Gohla S. In: Wise D, ed. Handbook of Pharmaceutical Controlled Release Technology. New York: Marcel Dekker, 2000:359.

35.Jenning V, Korting MS, Gohla S. Vitamin A loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 2000; 66:115.

36.Muhlen AZ, Schwarz C, Mehnert W. Solidlipid nanoparticles (SLNs) for controlled drug deliverdrug release and release mechanism. Eur J Pharm Biopharm 1998; 45:149.

37.Dulieu C, Bazile D. Influence of lipid nanocapsules composition on their aptness to freeze drying. Pharm Res 2005; 22:285.

38.Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rational for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47:3.

39.Jores K, Mehnert W, Drechesler M, Bunjes H, Johann C, Madder K. Investigations on the structure of solidlipid nanoparticles (SLN) and oil loaded solid lipid nanoparticles by photon correlation spectroscopy, field flow fractionation and transmission electron microscopy. J Control Release 2004; 95:217.

40.Muller RH, Radtke SA, Wissing SA. Solidlipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54:131.

41.Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved micro-encapsulation of drugs. Int J Pharm 2002; 242:121.

42.Chesnoy S, Huang L. Structure and function of lipid DNA complexes for gene delivery. Annu Rev Biophys Struct 2000; 29:27.43.Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucle-otides therapy against cancer. Adv Drug Deliv Rev 2001; 47:165.

44.Fournier E, Dufresne MH, Smith DC, Ranger M, Leroux JC. A novel step drug loading procedure for water soluble amphiphilic nanocarriers. Pharm Res 2004; 21:962.

45.Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion based process for the preparation of lipid nanocarriers. Pharm Res 2002; 19:875.

46.Tabatt K, Sameti M, Olbrich C, Muller RH, Lehr CM. Effect of cationic lipid and matrix lipid composition on solidlipid nanoparticles mediated gene transfer. Eur J Pharm Biopharm 2004; 57:155.

47.Rudolph C, Schillinger U, Ortiz A, Tabatt K, Plank C, Muller RH, Rosenecker J. Application of novel solidlipid (SLN) gene vector formulations based on a dimeric HIV-1 TAT pep-tide in vitro and in vivo. Pharm Res 2004; 21:1662.

48.Liu F, Yang J, Huang L, Liu D. New cationic lipid formulation for gene transfer. Pharm Res 1996; 13:1856.

49.Tabatt K, Kneuer C, Sameti M, et al. Transfection with different colloidal systems: com-parison of solidlipid nanoparticles and liposomes. J Control Release 2004; 97:321.

50.Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H. Development of a nonviral multifunctional envelop-type nanodevice by a novel lipid film hydration method. J Control Release 2004; 98:317.

51.Lee KE, Cho SH, Lee HB, Jeong SY, Yuk SH. Microencapsulation of lipid nanoparticles containing lipophilic drug. J Microencapsul 2003; 20:489.

52.Stevens PJ, Sekido M, Lee RJ. A folate receptor targeted lipid nanoparticles formulation for a lipophilic paclitaxel prodrug. Pharm Res 2004; 21:2153.

53.Hou DZ, Xie CS, Huang KJ, Zhu CH. The production and characteristics of solidlipid nanoparticles (SLNs). Biomaterials 2003; 24:1781.

54.Olbrich C, Gessner A, Schroder W, Kayser O, Muller RH. Lipiddrug conjugate nano-particles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum absorption. J Control Release 2004; 96:425.

55.Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR. Duodenal administration of solidlipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003; 92:1085.

56.Williams J, Lansdown R, Sweitzer R, Romanowski M, LaBell R, Ramaswami R, Unger E. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release 2003; 91:167.

57.Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002; 82:189.

58.Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001; 23:137.

59.Djordjevic J, Barch M, Uhrich E. Polymeric micelles based on amphiphilic scorpion like macro molecules: novel carriers for water insoluble drugs. Pharm Res 2005; 22:24.

60.Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Del Rev 2002; 54:113.

61.Kakizawa Y, Katakoa K. Block copolymer micelles for delivery of genes and related com-pounds. Adv Drug Del Rev 2002; 54:203.

62.Rosler A, Vandermeulen GM, Klok HA. Advanced drug delivery devices via self assem-bly of amphiphilic block copolymers. Adv Drug Del Rev 2001; 53:95.

63.Huh KM, Lee SC, Cho YW, Lee J, Jeong JH, Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release 2005; 101:59.

64.Kwon GS, Katakoa K. Block copolymers micelles as long circulating drug vehicles. Adv Drug Del Rev 1995; 16:295.

65.Burt HM, Zhang X, Toleikis P, Embree L, Hunter WL. Development of copolymers of poly(d,l lactide) and methoxypolyethylene glycol as micellar carriers for paclitaxel. Colloids Surf B Biointerfaces 1999; 16:161.

66.Fisher M, Vogtle F. Dendrimers: from design to applicationa progress report. Angew Chem Int Ed Engl 1999; 38:885.

67.Dufresne MH, Fournier F, Jones MC, Ranger M, Leroux JC. Block copolymers micellesengineering versatile carriers for drugs and biomacromolecules. In: Gurny R, ed.Challenges in Drug Delivery for the New Millennium. Saint Priest: Bulletin Technique Gattefosse96, 2003:103.

68.Kwon G, Suwa S, Yokoyama T, Okano T, Sakurai Y, Katakoa K. Enhanced tumor accumulation and prolonged circulation times of micelles forming poly(ethylene oxide-aspartate) block copolymeradriamycin conjugates. J Control Release 1994; 29:17.

69.Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nano-containers distribute to defined cytoplasmic organelles. Science 2003; 300:615.

70.Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65:271.

71.Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54:631.

72.Francis MF, Cristea M, Yang Y, Winnik FM. Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporine A across caco-2 cells. Pharm Res 2005; 22:209.

73.Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporine A in solidlipid nano-particles (SLN). Int J Pharm 2002; 241:341.

74.Varela MC, Guzman M, Molpeceres J, Aberturas MDR, Puyol DR, Puyol MR. Cyclosporine loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur J Pharm Sci 2001; 12:471.

75.Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso MJ. Development and characterization of Cy-A loaded polylacticpolyethylene glycol PEG micro and nano-particles: comparison with conventional PLA particulate carriers. Eur J Pharm Biopharm 2001; 51:111.

76.Campos AMD, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surfaces, application to cyclosporine A. Int J Pharm 2001; 224:159.

77.Gao ZG, Fain HD, Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release 2005; 102:203.

78.Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res 2001; 92:439.

79.Torchelin VP, Lukyanov AN, Gao A, Papahadjopoulos B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003; 100:6039.

80.Kabanov AV, Batrakova EV, Alakhov VY. An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J Control Release 2003; 91:75.

81.Na K, Lee KH, Bae YH. pH sensitivity and pH dependent interior structural change of self assembled hydrogel nanoparticles of pullulan acetate/oligo-sulfonamide conjugate. J Control Release 2004; 97:513.

82.Cammas S, Suzuki K, Sone C, Sakurai Y, Kataoka K, Okano T. Thermo responsive polymer nanoparticles with a core shell micelle structure as site specific drug carriers. J Control Release 1997; 48:157.

83.Chung JE, Yokoyama M, Yamato M, Aoyagi T, Sakurai Y, Okano T. Thermo responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate). J Control Release 1999; 62:115.

84.Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissues. Adv Drug Deliv Rev 2003; 55:329.

85.Vauthier C, Dubernet C, Fatal E, Alphandary HP, Couvreur P. Poly(alkylcyanoacrylates) as bio degradable materials for biomedical applications. Adv Drug Deliv Rev 2003; 55:519.

86.Discher DE, Eisenberg A. Polymeric vesicles. Science 2002; 297:967.

87.Harrington KJ, Lewanski CR, Stewart JSW. Liposomes as vehicles for targeted therapy of cancer. Part 2. Clinical development. Clin Oncol 2000; 12:16.

88.Xiong XY, Tam KC, Gan LH. Release kinetics of hydrophobic and hydrophilic model drugs from Pluronic F127/poly(lactic acid) nanoparticles. J Control Release 2005; 103:73.

89.Zhang L, Hu Y, Jiang X, Yang C, Lu W, Yang YH. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-c)-lactide nanoparticles and their bio-distribution in mice. J Control Release 2004; 96:135.90.Moghimi SM, Hunter AC, Murray JC. Long circulating and target specific nanoparti-cles: theory to practice. Pharmacol Rev 2001; 53:283.

91.Shenderova A, Burke TG, Schwendeman SP. Stabilization of 10-hydroxy camptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm Res 1997; 14:1406.

92.Hu Y, Jiang X, Ding Y, et al. Preparation and drug release behaviors of nimodipine-loaded poly(caprolactone)-poly-(ethylene oxide) polylactide amphiphilic copolymer nanoparticles. Biomaterials 2003; 24:2395.

93.Riley T, Stolnik S, Heald CR, et al. Physicochemical evaluation of nanoparticles assem-bled from poly(lactic acid) poly(ethylene glycol) (PLAPEG) block copolymers as drug delivery vehicles. Langmuir 2001; 17:3168. 94.Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 2004; 96:273.

95.Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide) block poly(l-amino acid) micelles for drug delivery. Adv Drug Deliv Rev 2002; 54:169.

96.Vriezema DM, Hoogboom J, Velonia K, et al. Vesicles and polymerized vesicles from thi-ophene containing rod coil block copolymers. Nolte Angew Chem Int Ed 2003; 42:772.

97.Vriezema DM, Kros A, Gelder RD, Cornelissen JJLM, Rowan AE, Roeland JM. Electroformed giant vesicles from thiophene containing rod coil diblock copolymers. Macromolecules 2004; 37:4736.

98.Vriezema DM, Araganoes MC, Elemans HAAW, Cornelissen JJLM, Rowan AE, Roeland JM. Self assembled nanoreactors. Chem Rev 2005; 105:1455.

99.Lee SC, Kim C, Kwon IC, Chung H, Jeong SY. Polymeric micelles of poly(2-ethyl-2- oxazoline)-blockpoly(caprolactone) copolymer as a carrier for paclitaxel. J Control Release 2003; 89:437.

100.Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release 2003; 93:151.

101.Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 2003; 86:33.

102.Chauvierre C, Labarre D, Couvreur P, Vauthier C. Novel polysaccharide decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm Res 2003; 20:1786.

103.Wartlick H, Schmitt SS, Strebhardt K, Kreuter J, Langer K. Tumor cell delivery of antisense oligonucleotides by human serum albumin nanoparticles. J Control Release 2004; 96:483.

104.Crommelin DJA, Strom G, Jiskot W, Stenekes R, Mastrobattista E, Hennink WE. Nanotechnological approaches for the delivery of macromolecules. J Control Release 2003; 87:81.

105.Ihre HR, Gagne L, Frechet JMJ, Szoka FC. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluations. Bioconjug Chem 2002; 13:453.

106.Liu MJ, Kono K, Frechet R. Water soluble dendritic unimolecular micelles, their poten-tial as drug delivery agents. J Control Release 2000; 65:121.

107.Zhang GD, Harada A, Nishiyama N, et al. Polyion complex micelles entrapping cati-onic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer. J Control Release 2003; 93:141.

108.Ueno Y, Futagawa H, Takagi Y, Ueno A, Mizushima Y. Drug incorporating calcium car-bonate nanoparticles for a new delivery system. J Control Release 2005; 103:93.

109.Vogel V, Lochmann D, Weyermann J, et al. Oligonucleotide-protamine-albumin nano-particles: preparation, physical properties and intracellular distribution. J Control Release 2005; 103:99.

110.Dinaure N, Lochmann D, Demirhan I, et al. Intracellular tracking of protamine/antisense oligo nucleotides nanoparticles and their inhibitory effect on HIV-1 transacti-vation. J Control Release 2004; 96:497.

111.Lochmann D, Vogel V, Weyermann J, et al. Physicochemical characterization of pro-tamine phosphorothioate nanoparticles. J Microencapsul 2004; 21:643.

112.Ando T, Yamasaki M, Suzuki K. Protamines: Isolation, Characterization, Structure and Function. Berlin: Springer, 1973.

113.Huang M, Khor E, Lim LY. Uptake and cytotoxicity of Chitosan molecules and nano-particles: effects of molecular weight and degree on deacetylation. Pharm Res 2004; 21:344.114.Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release 2001; 73:255.

115.Ma ZS, Lim LY. Uptake of Chitosan and associated insulin in the caco-2 call monolayers: a comparison between Chitosan molecules and Chitosan nanoparticles. Pharm Res 2002; 19:1488.

116.Illum L, Gill IJ, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51:81.

117.Campos AM, Diebold Y, Carvalho EL, Sanchez A, Alonso MJ. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate and cellular toxicity. Pharm Res 2004; 21:803.

118.Hejazi R, Amiji M. Chitosan based gastrointestinal delivery systems. J Control Release 2003; 89:151.

119.Park JH, Kwon S, Nam JO, et al. Self assembled nanoparticles based on glycol Chitosan bearing 5 B-cholanic acid for RGD peptide delivery. J Control Release 2005; 95:579.

120.De S, Robinson D. Polymer relationships during preparation of Chitosan-alginate and poly-l-lysine-alginate nanospheres. J Control Release 2003; 89:101.

121.Yoo HS, Lee JE, Chung H, Kwon IC, Jeong SY. Self assembled nanoparticles containing hydro phobically modified glycol Chitosan for gene delivery. J Control Release 2005; 103:235.

122.Kumar M, Kong X, Behera AK, Hellermann GR, Lockey RF, Mohapatra SS. Chitosan IFN-c-pDNA nanoparticles (CIN) therapy for allergic asthma. Gene Vaccines Ther 2001; 1:3.

123.Chu WH, Chin R, Huen T, Ferrari M. Silicone membrane nano-filters from sacrificial oxide removal. J Micro Electrochem Syst 1999; 8:34.

124.Martin F, Walczak R, Boiarski A, et al. Tailoring width of microfabricated nanochannels to solute size can be used to control diffusion kinetics. J Control Release 2005; 102:123.

125.Desai TA. Microfabrication technology for pancreatic cell encapsulation. Expert Opin Biol Therap 2002; 2:633.

126.Desai TA, Hansford D, Ferrari M. Characterization of micromachined silicone membranes for immunoisolation and bioseparation applications. J Membr Sci 1999; 159:221.

127.Lemarchand C, Couvreur P, Besnard M, Costantini D, Gref R. Novel polyesterpolysac-charide nanoparticles. Pharm Res 2003; 20:1284.

128.Muller BG, Leuenberger H, Kissel T. Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm Res 1996; 13:32.

129.Yamaguchi Y, Nagasawa T, Nakamura N, et al. Successful treatment of photodamaged skin of nano scale atRA particles using novel transdermal delivery. J Control Release 2005; 104:29.

130.Lim SJ, Kim CK. Formulation parameters determining the physicochemical characteris-tics of solidlipid nanoparticles loaded with all trans-retinoic acid. Int J Pharm 2002; 243:135.

131.Lim SJ, Lee MK, Kim CK. Altered chemical and biological activities of all trans incorpo-rated in solidlipid nanoparticles powders. J Control Release 2004; 100:53.

132.Balthasar S, Michaelis K, Dinauer N, Briesen VH, Kreuter J, Langer K. Preparation and characteri zation of antibody modified gelatin nanoparticles as carrier system for uptake in lymphocytes. Biomaterials 2005; 26:2723.

133.Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst 2002; 19:99.

134.Dalencon F, Amjaud Y, Lafforgue C, Derouin F, Fessi H. Atovaquone and rifabutine loaded nano capsules: formulation studies. Int J Pharm 1998; 153:127.

135.Hubert B, Atkinson J, Guerret M, Hoffman M, Devissaguet JP, Maincent P. The prepara-tion and acute antihypertensive effects of a nanoparticular form of darodipine, a dihy-dropyridine calcium entry blocker. Pharm Res 1991; 8:734.

136.Barrat G, Puisieux F, Yu WP, Foucher C, Fessi H, Devissaguet JP. Anti meta-static activ-ity of MDP-l-alanyl cholesterol incorporated into various types of nanocapsules. Int J Immuno-Pharmacol 1994; 16:457.

137.Calvo P, Alonso MJ, VilaJato JL, Robinson JR. Improved ocular bioavailability of Indomethacin by novel ocular drug carriers. J Pharm Pharmacol 1996; 48:1147.138.Chen H, Zhang Z, Almarsson O, Marier JF, Berkovitz D, Gardner CR. A novel lipid free nanodispersion formulation of propofol and its characterization. Pharm Res 2005; 22:356.

139.Zweers MLT, Engbers GHM, Grijpma DW, Feijen J. Vitro degradation of nanoparticles prepared from polymers based on dl-lactide glycolide and poly(ethylene oxide). J Control Release 2004; 100:347.

140.Arbos P, Campenero MA, Arangoa MA, Renedo MJ, Irache JM. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release 2003; 89:19.

141.Luu YK, Kim K, Hsiao BS, Chu B, Hadjiargurou M. Development of a nanostructured DNA delivery scaffold via electro-spinning of PLGA and PLAPEG block copolymers. J Control Release 2003; 89:341.

142.Murphy WL, Peters MC, Kohn DH, Mooney DJ. Sustained release of vascular endothe-lial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engi-neering. Biomaterials 2000; 24:2521.

143.Whang K, Goldstick TK, Healy KE. A biodegradable polymer scaffold for delivery of osteotropic factors. Biomaterials 2000; 24:2545.

144.Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Poly(lactic acid)poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 2001; 75:952.

145.Son YJ, Jang JS, Cho YW, et al. Biodistribution and antitumor efficacy of doxorubicin loaded glycol Chitosan nano-aggregates by EPR effect. J Control Release 2003; 91:135.

146.Nigavekar SS, Sung LY, Llanes M, et al. 3H dendrimer nanoparticles organ/tumor distribution. Pharm Res 2004; 21:476.

147.Balogh LP, Nigavekar SS, Cook AC, Minc L, Khan MK. Development of dendrimer gold radioactive nano-composites to treat cancer microvasculature. Pharma Chem 2003; 2:94.

148.Aneed AE. An overview of current delivery systems in cancer gene therapy. J Control Release 2004; 94:1.

149.Sakuma S, Sudo R, Suzuki N, Kikuchi H, Akashi M, Hayashi M. Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastroin-testinal tract. Int J Pharm 1999; 177:161.

150.Hayakawa T, Kawamura M, Okamoto M, Baba M, et al. Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: potential approach towards prevention of viral transmission. J Med Virol 1998; 56:327.

151.Akashi M, Niikawa T, Serizawa T, Hayakawa T, Baba M. Capture of HIV-1 gp120 and virions by lectin immobilized polystyrene. Bioconjug Chem 1998; 9:50.

152.Ogawara KI, Higaki K, Kimura T. Major determinants in hepatic disposition of polysty-rene nanospheres: implication for rational design of particulate drug carriers. Crit Rev Ther Drug Carrier Syst 2002; 19:45.

153.Ogawara KI, Furumoto K, Nagayama S, et al. Precoating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanospheres: implications for rational design of nanoparticles. J Control Release 2004; 100:451.

154.Bernkop-Schnurch A, Kast CE, Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release 2003; 93:95.

155.Li ZZ, Wen LX, Shao L, Chen JF. Fabrication of porous hollow silica nanoparticles and their applications in drug release control. J Control Release 2004; 98:245.

156.Zhou O, Shimoda H, Gao B, Oh S, Fleming L, Yue G. Materials science of carbon nano-tubes: fabri cation, integration and properties of macroscopic structures of carbon nano-tubes. Acc Chem Res 2002; 35:1045.

157.Iijima S. Helical microtubules of graphitic carbon. Nature 1991; 354:56.

158.Maurin G, Stepanek I, Bernier P, Colomer JF, Nagy JB, Henn F. Segmented and opened multiwalled carbon nanotubes. Carbon 2001; 39:1273.

159.Nanotechnology Now. Nanotubes survey, April 2003.

160. Nam JM, Thaxton CC, Mirkin CA. Nanoparticles based bio bar codes for the ultrasensi-tive detection of proteins. Science 2003; 301:1884.

161.Mahtab R, Rogers JP, Murphy CJ. Protein sized quantum dot luminescence can distin-guish between straight, bent and kinked oligonucleotides. J Am Chem Soc 1995; 117:9099.162.Cao YC, Jin R, Nam JM, Thaxton CS, Mirkin CA. Raman dye labeled nanoparticles probes for proteins. J Am Chem Soc 2003; 125:14676.

163.CMP Scientifica. Nanotech: The tiny revolution. copyrighted, 2001.

164.Salata OV. Applications of nanoparticles in biology and medicine. J Nanobiotechnol 2004; 2:3.

165.Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2003; 36:R167.

166.Reich DH, Tanase M, Hultgren A, Bauer LA, Chen CS, Meyer GJ. Biological applications of multifunctional magnetic nanowires. J Appl Phys 2003; 93:7275.

167.Kast CE, Guggi D, Langoth N, Bernkop-Schnurch A. Development and in vivo evalua-tion of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm Res 2003; 20:931.

168.Bernkop-Schnurch A, Hoffer MH, Krum K. Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin Drug Deliv 2004; 1:87.

169.Leitner VM, Guggi D, Krauland AH, Bernkop-Schnurch A. Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/GSH microparticulate delivery system. J Control Release 2004; 100:87.

170.Commercially available nanoparticles and nanospheres for medical applications. www. microspheres-nanospheres.com.

171.Yin SX, Franchini M, Chen J, et al. Bioavailability enhancement of a COX-2 inhibitor BMS-347070, from a nanocrystalline dispersion prepared by spray drying. J Pharm Sci 2005; 94:1598.

172.Tyner KM, Schiffman SR, Giannelis EP. Nanohybrids as delivery vehicles for camp-tothecin. J Control Release 2004; 95:501.

173.Tyner KM, Roberson MS, Berghorn KA, et al. Intercalation, delivery and expression of the gene encoding green fluorescence protein utilizing nanohybrids. J Control Release 2004; 100:399.

174.Broz P, Benito SM, Saw CL, et al. Cell targeting by a generic receptor targeted polymer nanocontainer platform. J Control Release 2005; 102:475.

175.Reneker DH, Chun I. Nanometer diameter of polymer, produced by electrospinning. Nanotechnology 1996; 7:216.

176.Kath DS, Robinson KW, Attawia MA, Ko FW, Laurencin CT. Bioresorbable nanofiber based systems for wound healing: optimization of fabrication parameters. Transactions of the 28th Annual Meeting for the Society of Biomaterials, 2002:143.

177.Verreck G, Chun I, Peeters J, Rosenblatt J, Brewster ME. Preparation and characteriza-tion of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Pharm Res 2003; 20:810.

178.Verreck G, Chun I, Rosenblatt J, et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water insoluble non-biodegradable polymer. J Control Release 2003; 92:349.

. .

(1). 1990 . (2). . . (34). ) ) ) . . . . (5). . (6). (7). (8). (9) (10) . . . (11) (12) (13) (14) (15) . (16) (17) . (18). (19). . .

() . . . . . . . - (20). . . .

. . . . () 2r- (r ) . (6r-) (21). . . . . . . : . . . (22). () . . . . . . . . (1) . (PSI 50000-5000) . . . . . . . (23). 300 2 . . . . . . . . . . () . pH . ( ) (24) logP . .

( 1) . ( ) . ( ). . . (21). . (28-25) . . ( ppm) . . (29).

1. . . .

. . . . . - () (2930). . 2 . . ( pH) (3132). (33). (34). . 4 Cmax 30 ( A2). ( B2). ( A2). Cmax AUC ( D2). . . ( C2). .

2. (PK) . (A) . (B) PK . (C) PK . (D) PK . 40 (35). : () () .

. 7 . 12 (36) . (37).

20 500 . 40 80 . 40 (37).

7 (38) (3940). 8 . . 10 40 . 1068 4/0 10 1054 40 . . (MPS) . 5/4-2 93% 10 32 . 1085 1088 7/8 (41). 1097 1079/9 . . . 8-4 . 90% 10 70 20 40 . 150 . 200000 700000 350000 (42). USP 300 25 . USP . . 1 . 1 4 . 1. (m) ( )

3/1 1096 PK (43)

17/1-5/0 10126/1 PK (45)

10 4 4/0 1068 (39)

4/3 10101 (48)

7/3 1084/2 (40)

4/3 2 1079/8 (36)

5/4-0/2 1079/9 (41)

4/0 10125/2 ( )

4/0 10123/1 ( )

- . (51). . (52) (5354) (55). ( ) (56). (57).

(58). -HI . 80% 100 500 ( ) 5 . 3/0 . . 10% 2/14/43 (9=n) 1% 8/15/8 (9=n). . 10% 10 . 5% . . 1 10% . 14 (59). . . . 72 . 10% 1% 5% . (60). . 5/1% 30/70 / (61). 5/0 ID . 72 : 0 2 0 2 0 2 0 2 0 2 . . 250 7/06 (P